血浆血管紧张素Ⅱ1型受体及其抗体与血压的关系
|
摘要
背景:血管紧张素Ⅱ1型受体与高血压的发生发展密切相关,且高血压患者外周血中已检出其自身抗体。
目的:探讨血管紧张素Ⅱ1型受体(AT_1R)及其自身抗体(AT_1R-AA)与血压及炎性因子的关系。
方法:采用横断面研究方法,从体检人群中随机调查138例为研究对象,根据美国预防、检测、评估与治疗高血压全国联合委员会第7次报告(JNC 7)将入选对象分为3组:正常血压组31例(≤120/80 mm Hg)、高血压前期组39例(120—139/80—89 mm Hg)、高血压组68例(≥140/90 mm Hg);采用酶联免疫吸附技术(ELISA)检测血浆AT_1R及AT_1R-AA的水平,用放射免疫法检测肿瘤坏死因子-α(TNF-α)、内皮素-1(ET-1)及血管紧张素Ⅱ(AngⅡ)的水平;用自动生化分析仪检测血脂水平。
结果:1)血浆AT_1R、AT_1R-AA、TNF-α、ET-1、AngⅡ的水平随血压水平的升高而增加;2)AT_1R及AT_1R-AA与收缩压、舒张压、平均动脉压、TNF-α、ET-1、AngⅡ的水平呈正相关,AngⅡ与收缩压、舒张压、平均动脉压及ET-1的水平呈正相关;3)多元线性回归分析显示,AT_1R、AT_1R-AA及AngⅡ是收缩压、平均动脉压的独立影响因素,AT_1R、AT_1R-AA是舒张压的独立影响因素。
结论:血浆AT_1R、AT_1R-AA的表达水平可反映血压的水平,且AT_1R-AA的水平与炎症因子密切相关,可能在高血压发生发展中起一定作用。
Background: Angiotensin II type 1 receptor is closely related to hypertension, and new evidence has suggested that the autoantibodies to AT_1R are present in hypertensive people.
Objective: To investigate the relationship of angio- tensin II type 1 receptor (AT_1R), antibodies against angiotensin II Type 1 receptor (AT_1R-AA) and blood pressure.
Methods: One hundred and thirty-eight subjects were enrolled and separated into three groups according to the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): normotensive (≤120/80 mm Hg, n=31), pre- hypertensive (120—139/80—89 mm Hg, n=39) and hypertensive (≥140/90 mm Hg, n=68) groups. Plasma AT_1R and AT_1R-AA were detected by Enzyme-linked immunosorbent assay (ELISA), tumor necrosis factor-α(TNF-α), endothelin-1 (ET-1) and angiotensin II (Ang II) by radioimmunity. Results: 1) Plasma levels of AT_1R/ AT1- AA, TNF-α, ET-1 and Ang II are increased with blood pressure levels. 2) Plasma AT_1R/AT_1R-AA are positively correlated with systolic blood pressure,diastolic blood pressure, mean arterial pressure, TNF-α, ET-1 and Ang II, Ang II are also positively correlated with systolic blood pressure,diastolic blood pressure, mean arterial pressure and ET-1. 3) Multipule linear regression analysis showed that AT_1R, AT_1R-AA and Ang II are independent predictors for systolic blood pressure, mean arterial pressure, AT_1R, AT_1R-AA are independent predictors for diastolic blood pressure.
Conclusion: The expression levels of plasma AT_1R/AT_1R-AA may reflect the levels of blood pressure. And AT_1R-AA is closely related with inflammatory factors, which may also play an important role in the progress of hypertension.
目的:探讨血管紧张素Ⅱ1型受体(AT_1R)及其自身抗体(AT_1R-AA)与血压及炎性因子的关系。
方法:采用横断面研究方法,从体检人群中随机调查138例为研究对象,根据美国预防、检测、评估与治疗高血压全国联合委员会第7次报告(JNC 7)将入选对象分为3组:正常血压组31例(≤120/80 mm Hg)、高血压前期组39例(120—139/80—89 mm Hg)、高血压组68例(≥140/90 mm Hg);采用酶联免疫吸附技术(ELISA)检测血浆AT_1R及AT_1R-AA的水平,用放射免疫法检测肿瘤坏死因子-α(TNF-α)、内皮素-1(ET-1)及血管紧张素Ⅱ(AngⅡ)的水平;用自动生化分析仪检测血脂水平。
结果:1)血浆AT_1R、AT_1R-AA、TNF-α、ET-1、AngⅡ的水平随血压水平的升高而增加;2)AT_1R及AT_1R-AA与收缩压、舒张压、平均动脉压、TNF-α、ET-1、AngⅡ的水平呈正相关,AngⅡ与收缩压、舒张压、平均动脉压及ET-1的水平呈正相关;3)多元线性回归分析显示,AT_1R、AT_1R-AA及AngⅡ是收缩压、平均动脉压的独立影响因素,AT_1R、AT_1R-AA是舒张压的独立影响因素。
结论:血浆AT_1R、AT_1R-AA的表达水平可反映血压的水平,且AT_1R-AA的水平与炎症因子密切相关,可能在高血压发生发展中起一定作用。
Background: Angiotensin II type 1 receptor is closely related to hypertension, and new evidence has suggested that the autoantibodies to AT_1R are present in hypertensive people.
Objective: To investigate the relationship of angio- tensin II type 1 receptor (AT_1R), antibodies against angiotensin II Type 1 receptor (AT_1R-AA) and blood pressure.
Methods: One hundred and thirty-eight subjects were enrolled and separated into three groups according to the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): normotensive (≤120/80 mm Hg, n=31), pre- hypertensive (120—139/80—89 mm Hg, n=39) and hypertensive (≥140/90 mm Hg, n=68) groups. Plasma AT_1R and AT_1R-AA were detected by Enzyme-linked immunosorbent assay (ELISA), tumor necrosis factor-α(TNF-α), endothelin-1 (ET-1) and angiotensin II (Ang II) by radioimmunity. Results: 1) Plasma levels of AT_1R/ AT1- AA, TNF-α, ET-1 and Ang II are increased with blood pressure levels. 2) Plasma AT_1R/AT_1R-AA are positively correlated with systolic blood pressure,diastolic blood pressure, mean arterial pressure, TNF-α, ET-1 and Ang II, Ang II are also positively correlated with systolic blood pressure,diastolic blood pressure, mean arterial pressure and ET-1. 3) Multipule linear regression analysis showed that AT_1R, AT_1R-AA and Ang II are independent predictors for systolic blood pressure, mean arterial pressure, AT_1R, AT_1R-AA are independent predictors for diastolic blood pressure.
Conclusion: The expression levels of plasma AT_1R/AT_1R-AA may reflect the levels of blood pressure. And AT_1R-AA is closely related with inflammatory factors, which may also play an important role in the progress of hypertension.
引文
[1] de Gasparo M, Catt KJ, Inagami T, et al. International Union of Pharmacology. XXIII. The angiotensinⅡreceptors[J]. Pharmacol Rev, 2000, 52: 415–472.
[2] Mogi M, Iwai M, Horiuchi M. New insights into the regulation of angiotensin receptors[J]. Curr Opin Nephrol Hypertens, 2009, 18: 138-143.
[3]仇燕,朱峰,廖玉华,等.高血压病患者血清抗血管紧张素Ⅱ1型受体自身抗体与心脏重构的相关分析[J].中华心血管病杂志,2007, 35: 1141-1144.
[4]陈秀梅,卢新政,占伊扬,等.血管紧张素Ⅱ2型受体自身抗体与血压水平及肾功能的关系[J].中华高血压杂志,2008, 16: 1071-1075.
[5] Hu L, Zhu DN, Yu Z, et al. Expression of angiotensin II type 1 (AT(1)) receptor in the rostral ventrolateral medulla in rats[J]. J Appl Physiol, 2002, 92: 2153- 2161.
[6] Yayama K, Horii M, Hiyoshi H, et al. Up-regulation of angiotensin II type 2 receptor in rat thoracic aorta by pressure-overload[J]. J Pharmacol Exp Ther, 2004, 308: 736-43.
[7] Allen AM, Zhuo J, Mendelsohn FA. Localization and function of angiotensin AT1 receptors[J]. Am J Hypertens, 2000, 13: 31S-38S.
[8] Reja V, Goodchild AK, Phillips JK, et al. Upregulation of angiotensin AT1 receptor and intracellular kinase gene expression in hypertensive rats[J]. Clin Exp Pharmacol Physiol, 2006, 33: 690–695.
[9] Paxton WG, Runge M, Horaist C, et al. Immunohistochemical localization of rat angiotensinⅡAT1 receptor[J]. Am J Physiol, 1993, 33: F989–F995.
[10] Banday AA, Lokhandwala MF. Loss of biphasic effect on Na/K-ATPase activity by angiotensinⅡinvolves defective angiotensin type 1 receptor-nitric oxide signaling[J]. Hypertension, 2008, 52: 1099-1105.
[11] Hanna IR, Taniyama Y, Szocs K, et al. NADPH oxidase-derived reactiveoxygen species as mediators of angiotensinⅡsignaling[J]. Antioxid Redox Signal, 2002, 4: 899–914.
[12] Gill PS, Wilcox CS. NADPH oxidases in the kidney[J]. Antioxid Redox Signal, 2006, 8: 1597–1607.
[13] Elton TS, Martin MM. Angiotensin II type 1 receptor gene regulation: transcriptional and posttranscriptional mechanisms[J]. Hypertension, 2007, 49 (5): 953-961.
[14] Fu ML, Herlitz H, Wallukat G, et al. Functional autoimmune epitope on alpha 1-adrenergic receptors in patients with malignant hypertension[J]. Lancet, 1994, 344(8938): 1660-1663.
[15] Wallukat G, Homuth V, Fischer T, et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor[J]. J Clin Invest, 1999, 103 (7): 945-952.
[16] Dechend R, Homuth V, Wallukat G, et al. AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor[J]. Circulation, 2000, 101 (20): 2382-2387.
[17] Dechend R, Müller DN, Wallukat G, et al. AT1 receptor agonistic antibodies, hypertension, and preeclampsia[J]. SemSemin Nephrol, 2004, 24(6): 571-579.
[18] Wallukat G, Homuth V, Fischer T, et al. Patients with pre-eclampsia develop agonistic antibodies against the angiotensin AT1R receptor[J]. J Clin Invest, 1999, 103: 945-952.
[19] Sun YX, Zhang HY, Wei YM, et al. The mechanism of signal transduction during vascular smooth muscle cell proliferation induced by autoantibodies against angiotensin AT1 receptor from hypertension[J]. Chin Med J (Engl) , 2008, 121: 43-48.
[20] Yang X, Wang F, Chang H, et al. Autoantibody against AT1 receptor frompreeclamptic patients induces vasoconstriction through angiotensin receptor activation[J]. J Hypertens, 2008, 26: 1629-1635.
[21] LaMarca B, Parrish M, Ray LF, et al. Hypertension in response to auto- antibodies to the angiotensinⅡtype I receptor (AT1-AA) in pregnant rats: role of endothelin-1[J]. Hypertension, 2009, 54: 905-909.
[22] LaMarca B, Wallukat G, Llinas M, et al. Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor alpha in pregnant rats[J]. Hypertension, 2008, 52: 1168-1172.
[23] Parameswaran N, Patial S. Tumor Necrosis Factor-αSignaling in Macrophages [J]. Crit Rev Eukaryot Gene Expr, 2010, 20(2): 87-103.
[24] Clark IA. How TNF was recognized as a key mechanism of disease[J]. Cytokine Growth Factor Rev, 2007, 18(3–4): 335–343.
[25] Kadokami T, McTiernan CF, Kubota T, et al. Sex-related survival differences in murine cardiomyopathy are associated with differences in TNF-receptor expression[J]. J Clin Invest, 2000, 106: 589–597.
[26] Luo D, Luo Y, He Y, et al. Differential functions of tumor necrosis factor receptor 1 and 2 signaling in ischemiamediated arteriogenesis and angiogenesis. Am J Pathol, 2006, 169: 1886–1898.
[27] Kleinbongard P, Schulz R, Heusch G. TNFαin myocardial ischemia/reperfusion, remodeling and heart failure[J]. Heart Fail Rev, 2011, 16(1): 49-69.
[28] Aker S, Belosjorow S, Konietzka I, et al. Serum but not myocardial TNF-a concentration is increased in pacing-induced heart failure in rabbits[J]. Am J Physiol Regul Integr Comp Physiol, 2003, 285: R463–R469.
[29] Marin-Garcia J, Goldenthal MJ, Moe GW. Abnormal cardiac and skeletal muscle mitochond -rial function in pacinginduced cardiac failure[J]. Cardiovasc Res, 2001, 52: 103–110.
[30] Petretta M, Gian L, Condorelli MD, et al. Circulating levels of cytokines and their site of production in patients with mild to severe chronic heart failure[J]. Am Heart J, 2000, 140(6): E28.
[31] Valgimigli M, Ceconi C, Malagutti P, et al. Tumor necrosis factor-a receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction. The cytokine-activation and long-term prognosis in myocardial infarction (C-ALPHA) study[J]. Circulation, 2005, 111: 863–870.
[32] Nikolopoulou A, Tousoulis D, Antoniades C, et al. Common community infecti- ons and the risk for coronary artery disease and acute myocardial infarction: evidence for chronic over-expression of tumor necrosis factor alpha and vascular cells adhesion molecule-1[J]. Int J Cardiol, 2008, 130: 246–250.
[33] Tuomisto K, Jousilahti P, Sundvall J, et al. C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardio- vascular events and total mortality. A population-based, prospective study[J]. Thromb Haemost, 2006, 95: 511–518.
[34] Dinh W, Futh R, Nickl W, et al. Elevated plasma levels of TNF-alpha and interleukin-6 in patients with diastolic dysfunction and glucose metabolism disorders[J]. Cardiovasc Diabetol, 2009, 8:58.
[35] Li JJ, Chen JI. Inflammation may be a bridge connecting hypertension and atheroslerosis[J]. Med Hypotheses, 2005, 64(5): 925-929.
[36] Bautista LE, Vera LM, Arenas IA, et al. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension[J]. J Hum Hypertens, 2005, 19: 149-154.
[37] Kawanabe Y, Nauli SM. Endothelin[J]. Cell Mol Life Sci, 2011, 68(2):195–203.
[38] Price LC, Howard LS. Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy[J]. Am J Cardiovasc Drugs, 2008, 8:171–185.
[39] Shao D, Park JE, Wort SJ.The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension. Pharmacol Res. 2011, [Epub ahead of print].
[40]王平,匡希斌.内皮素-1与原发性高血压[J].心血管病学进展,2007, 28(2):318-320.
[41] Bautista LE, Vera LM, Arenas IA, et al. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension[J]. J Hum Hypertens, 2005, 19(2): 149-154.
[42] Leah S, Jason AP, Mon HS, et al. Endothelin-induced increases in Ca2+ entry mechanisms of vascular contraction are enhanced during high-salt diet[J]. Hypertension, 2003, 41 (part 2): 787-793.
[43] Petnehazy T, Stokes KY, Russell JM, et al. Angiotensin II type-1 receptor antagonism attenuates the inflammatory and thromhogenie responses to hyper- cholesterolemia in venules[J]. Hypertension, 2005, 45(2): 209-215.
[44] Tan M, Lee YJ, Shin SJ, et al. Oxidized low-density lipoprotein stimulates endothlin-1 release and mRNA expression form rat mesangial cells[J]. J Iab Clin Med, 1997, 129: 224-230.
[45] Lüscher TF. Endothelial dysfunction: the role and impact of the renin- angiotensin system[J]. Heart, 2000, 84: i20-i22.
[46]程虹,湛贻璞.内皮素-1与肾素-血管紧张素-醛固酮系统的相互作用[J].肾脏病与透析肾移植杂志,2003, 12(4): 371-374.
[1] Guimar?es S, Pinheiro H. Functional evidence that in the cardiovascular system AT1 angiotensin II receptors are AT1B prejunctionally and AT1A postjunc- tionally[J]. Cardiovasc Res, 2005, 67(2): 208-215.
[2] Saito M, Shinohara Y, Sasaki H, et al. Type 1 angiotensin receptor (AT1-R)- mediated decrease in type 2 angiotensin receptor mRNA level is dependent on Gq and extracellular signal regulated kinase 1//2 in AT1-R-transfected PC12 cells[J]. J Neuroendocrinol, 2008, 20(3): 299-308.
[3] von Bohlen und Halbach O, Albrecht D. The CNS renin-angiotensin system[J]. Cell Tissue Res, 2006, 326(2): 599–616.
[4] Gallinat S, Busche S, Raizada MK, et al.The angiotensin II type 2 receptor: an enigma with multiple variations[J]. Am J Physiol Endocrinol Metab, 2000, 278 (3): E357-E374.
[5] Coffman TM. A genetic approach for studying the physiology of the type 1A (AT1A) angiotensin receptor[J]. Semin Nephrol, 1997, 17(5): 404-411.
[6] Zhou Y, Dirksen WP, Chen Y, et al. A major role for AT1b receptor in mouse mesenteric resistance vessels and its distribution in heart and neuroendocrine tissues[J]. J Mol Cell Cardiol, 2005, 38(4): 693– 696.
[7] Wright JW, Harding JW. Brain angiotensin receptor subtypes AT1, AT2, and AT4 and their functions[J]. Regul Pept, 1995, 59(3): 269-295.
[8] Vanderheyden PM. From angiotensin IV binding site to AT4 receptor[J]. Mol Cell Endocrinol, 2009, 302(2): 159-166.
[9] Paxton WG, Runge M, Horaist C, et al. Immunohistochemical localization of rat angiotensin II AT1 receptor[J]. Am J Physiol, 1993, (6 Pt 2): F989–F995.
[10] Li Z, Iwai M, Wu L, et al. Role of AT2 receptor in the brain in regulation of blood pressure and water intake[J]. Am J Physiol Heart Circ Physiol, 2003,284(1): H116 - H121.
[11] Wright JW, Harding JW. The angiotensin AT4 receptor subtype as a target for the treatment of memory dysfunction associated with Alzheimer's disease[J]. J Renin Angiotensin Aldosterone Syst, 2008, 9(4): 226-237.
[12] Fu ML, Herlitz H, Wallukat G, et al. Functional autoimmune epitope on alpha 1-adrenergic receptors in patients with malignant hypertension[J]. Lancet, 1994, 344(8938): 1660-1663.
[13] Wallukat G, Homuth V, Fischer T, et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor[J]. J Clin Invest, 1999, 103(7): 945-952.
[14] Dechend R, Homuth V, Wallukat G, et al. AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor[J]. Circulation, 2000, 101 (20): 2382-2387.
[15] Dechend R, Müller DN, Wallukat G, et al. AT1 receptor agonistic antibodies, hypertension, and preeclampsia[J]. SemSemin Nephrol, 2004, 24(6): 571-579.
[16] Yang X, Wang F, Chang H, et al. Autoantibody against AT1 receptor from preeclamptic patients induces vasoconstriction through angiotensin receptor activation[J]. J Hypertens, 2008, 26: 1629-1635.
[17] LaMarca B, Parrish M, Ray LF, et al. Hypertension in response to auto- antibodies to the angiotensinⅡtype I receptor (AT1-AA) in pregnant rats: role of endothelin-1[J]. Hypertension, 2009, 54: 905-909.
[18]陈秀梅,卢新政,占伊扬,等.血管紧张素Ⅱ2型受体自身抗体与血压水平及肾功能的关系[J].中华高血压杂志,2008, 16(12): 1071-1075.
[19] Elton TS, Martin MM. Angiotensin II type 1 receptor gene regulation: transcriptional and posttranscriptional mechanisms[J]. Hypertension, 2007, 49 (5): 953-961.
[20] Zhu YC, Zhu YZ, Lu N, et al. Role of angiotensin AT1 and AT2 receptors in cardiac hypertrophy and cardiac remodelling[J]. Clin Exp Pharmacol Physiol, 2003, 30(12): 911-918.
[21] Kim HJ, Ryu JH, Han SW, et al. Combined therapy of cilazapril and losartan has no additive effects in ameliorating adriamycin-induced glomerulopathy[J]. Nephron Physiol, 2004, 97 (4): p58-65.
[22] Reja V, Goodchild AK, Phillips JK, et al. Upregulation of angiotensin AT1 receptor and intracellular kinase gene expression in hypertensive rats[J]. Clin Exp Pharmacol Physiol, 2006, 33(8): 690–695.
[23] Zhou J, Pavel J, Macova M, et al. AT1 receptor blockade regulates the local angiotensin II system in cerebral microvessels from spontaneously hypertensive rats[J]. Stroke, 2006, 37(5): 1271–1276.
[24] Iwai M, Horiuchi M.Devil and angel in the renin–angiotensin system: ACE– angiotensin II–AT1 receptor axis vs. ACE2–angiotensin-(1–7)–Mas receptor axis[J]. Hypertens Res, 2009, 32(7): 533-536.
[25] Kiribayashi K, Masaki T, Naito T, et al. Angiotensin II induces fibronectin expression in human peritoneal mesothelial cells via ERK1/2 and p38 MAPK[J]. Kidney Int, 2005, 67(3): 1126–1135.
[26] Dilauro M, Burns KD. Angiotensin-(1-7) and its effects in the kidney[J]. Scientific World Journal, 2009, 9: 522-535.
[27] Ushio-Fukai M, Alexander RW. Caveolin-dependent angiotensin II type 1 receptor signaling in vascular smooth muscle[J]. Hypertension, 2006, 48(5): 797 -803.
[28] CalòLA, Schiavo S, Davis PA, et al. Angiotensin II signaling via type 2 receptors in a human model of vascular hyporeactivity: implications for hypertension[J]. J Hypertens, 2010, 28(1): 111–118.
[29]首云锋,陈明.血管紧张素受体AT2及AT4研究进展[J].心血管病学进展,2010, 31(1): 58-61.
[30] Chai SY, Fernando R, Peck G, et al. The angiotensin IV/AT4 receptor[J].Cell Mol Life Sci, 2004, 61(21): 2728-2737.
[31] Zorad S, Dou JT, Benicky J, et al. Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARc [J]. Eur J Pharmacol, 2006, 552(1-3): 112–122.
[32] Inaba S, Iwai M, Tomono Y, et al. Exaggeration of focal cerebral ischemia in transgenic mice carrying human Renin and human angiotensinogen genes[J]. Stroke, 2009, 40(2): 597-603.
[33] Horiuchi M, Mogi M, Iwai M. The angiotensin II type 2 receptor in the brain[J]. J Renin Angiotensin Aldosterone Syst, 2010, 11(1): 1-6.
[34] Sakata A, Mogi M, Iwanami J, et al. Sex-different effect of angiotensin II type 2 receptor on ischemic brain injury and cognitive function[J]. Brain Res, 2009, 1300: 14-23.
[35] Wu CK, Tsai CT, Chang YC, et al. Genetic polymorphisms of the angiotensin II type 1 receptor gene and diastolic heart failure[J]. J Hypertens, 2009, 27(3): 502–507.
[36] Wang JL, Xue L, Hao PP,et al. Angiotensin II type 1 receptor gene A1166C polymorphism and essential hypertension in Chinese: a meta-analysis[J]. J Renin Angiotensin Aldosterone Syst, 2010, 11(2): 127-35.
[37] Gao L, Wang WZ, Wang W, et al. Imbalance of angiotensin type 1 receptor and angiotensin II type 2 receptor in the rostral ventrolateral medulla: potential mechanism for sympathetic overactivity in heart failure[J]. Hypertension, 2008, 52(4): 708-714.
[38] Smith GR, Missailidis S. Cancer, inflammation and the AT1 and AT2 receptors [J]. J Inflamm (Lond), 2004, 1(1):3.
[39] De Paepe B, Verstraeten VL, De Potter CR, et al. Growth stimulatory angiotensin II type-1 receptor is upregulated in breast hyperplasia and in situ carcinoma but not in invasive carcinoma[J]. Histochem Cell Biol, 2001, 116(3): 247-254.
[40] Takeda H, Kondo S. Differences between squamous cell carcinoma and keratoa- canthoma in angiotensin type-1 receptor expression[J]. Am J Pathol, 2001, 158 (5): 1633-1637.
[41] Kikkawa F, Mizuno M, Shibata K, et al. Activation of invasiveness of cervical carcinoma cells by angiotensin II[J]. Am J Obstet Gynecol, 2004, 190(5): 1258 -1263.
[42] Suganuma T, Ino K, Shibata K, et al. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination[J]. Clin Cancer Res, 2005, 11(7): 2686-2694.
[43] Fujita M, Hayashi I, Yamashina S, e tal. Angiotensin type 1a receptor signaling- dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth[J]. Carcinogenesis, 2005, 26(2): 271-279.
[44] Faure S, Javellaud J, Achard JM, et al. Vasoconstrictive effect of angiotensin IV in isolated rat basilar artery independent of AT1 and AT2 receptors[J]. J Vasc Res, 2006, 43(1): 19-26.
[45] Lochard N, Thibault G, Silversides DW, et al. Chronic production of angiotensin IV in the brain leads to hypertension that is reversible with an angiotensin II AT1 receptor antagonist[J]. Circ Res, 2004, 94(11): 1451-1457.
[46] Williams PJ, Mistry HD, Innes BA, et al. Expression of AT1R, AT2R and AT4R and their roles in extravillous trophoblast invasion in the human[J]. Placenta, 2010, 31(5): 448-455.
[1] Santos RA, Ferreira AJ,Simoes e AC. Recent advances in the angiotensin converting enzyme 2-angiotensin(1-7)-Mas axis[J]. Exp Physiol, 2008, 93(5): 519–527.
[2] Santos RA, Simoes e Silva AC, Maric C, et al. Angiotensin-(1-7) is an endogenous ligand for the G-protein coupled receptor Mas[J]. Proc Natl Acad Sci U S A, 2003, 100(14): 8258-8263.
[3] Iwai M, Horiuchi M. Devil and angel in the renin–angiotensin system: ACE– angiotensin II–AT1 receptor axis vs. ACE2–angiotensin-(1–7)–Mas receptor axis[J]. Hypertens Res, 2009, 32(7): 533-536.
[4] Xu P, Costa-Goncalves AC, Todiras M, et al. Endothelial Dysfunction and Elevated Blood Pressure in Mas Gene-Deleted Mice[J]. Hypertension, 2008, 51 (2): 574-580.
[5] Towler P, Staker B, Prasad SG, et al. ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis[J]. J Biol Chem, 2004, 279(17): 17996-18007.
[6] Harmer D, Gilbert M, Borman R, et al. Quantitative mRNA expression profiling of ACE2, a novel homologue of angiotensin converting enzyme[J]. FEBS Lett, 2002, 532(1-2): 107-110.
[7] Vickers C, Hales P, Kaushik V, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase[J]. J Biol Chem, 2002, 277(17): 14838-14843.
[8] Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function[J]. Nature, 2002, 417(6891): 822-828.
[9] Santos RA, Brosnihan KB, Jacobsen DW, et al. Production of angiotensin-(1-7) by human vascular endothelium[J]. Hypertension, 1992, 19(2): II56–61.
[10] Joyner J, Neves LA, Granger JP, et al. Temporal-spatial expression of ANG-(1-7) and angiotensin-converting enzyme 2 in the kidney of normal and hypertensive pregnant rats[J]. Am J Physiol Regul Integr Comp Physiol, 2007, 293(1): R169– 177.
[11] Ferrario CM, Martell N, Yunis C, et al. Characterization of angiotensin-(1-7) in the urine of normal and essential hypertensive subjects[J]. Am J Hypertens, 1998, 11(2): 137–146.
[12] Dilauro M, Burns KD. Angiotensin-(1-7) and its effects in the kidney[J]. Scientific World Journal, 2009, 9: 522-535.
[13] Alenina N, Xu P, Rentzsch B, et al. Genetically altered animal models for Mas and angiotensin-(1-7) [J]. Exp Physiol, 2008, 93(5): 528-537.
[14] Burstein ES, Ott TR, Feddock M, et al. Characterization of the Mas-related gene family: structural and functional conservation of human and rhesus MrgX receptors[J]. Br J Pharmacol, 2006, 147(1): 73–82.
[15] Young D, O’Neill K, Jessell T, et al. Characterization of the rat mas oncogene and its high-level expression in the hippocampus and cerebral cortex of rat brain[J]. Proc Natl Acad Sci U S A, 1988, 85(14): 5339–5342.
[16] Alenina N, Baranova T, Smirnow E, et al. Cell type-specific expression of the Mas proto-oncogene in testis[J]. J Histochem Cytochem, 2002; 50(5): 691-696.
[17] Villar AJ, Pedersen RA. Parental imprinting of the Mas protooncogene in mouse[J]. Nature Genet, 1994, 8(4): 373–379.
[18] Metzger R, Bader M, Ludwig T, et al. Expression of the mouse and rat mas proto-oncogene in the brain and peripheral tissues[J]. FEBS Lett, 1995, 357 (1): 27–32.
[19] da Costa Gon?alves AC, Leite R, Fraga-Silva RA, et al. Evidence that the vasodilator angiotensin-(1–7)-Mas axis plays an essential role in erectilefunction[J]. Am J Physiol Heart Circ Physiol, 2007, 293(4): H2588–H2596.
[20] Schluter KD, Wenzel S. Angiotensin II: a hormone involved in and contributing to prohypertrophic cardiac networks and target of anti-hypertrophic cross- talks[J]. Pharmacol Ther, 2008, 119(3): 311–325.
[21] Frank D, Kuhn C, van Eickels M, et al. Calsarcin-1 protects against angiotensin- II induced cardiac hypertrophy[J]. Circulation, 2007, 116(22): 2587–2596.
[22] Gomes ER, Lara AA, Almeida PW, et al. Angiotensin-(1-7) prevents cardio- myocyte pathological remodeling through a nitric oxide/guanosine 3',5'- cyclic monophosphate dependent pathway[J]. Hypertension, 2010, 55(1): 153 -160.
[23] Beals CR, Sheridan CM, Turck CW, et al. Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3[J]. Science, 1997, 275(5308): 1930–1934.
[24] Su Z, Zimpelmann J, Burns KD. Angiotensin-(1-7) inhibits angiotensin II- stimulated phosphorylation of MAP kinases in proximal tubular cells[J]. Kidney Int, 2006, 69 (12): 2212–2218.
[25] Gava E, Samad-Zadeh A, Zimpelmann J, et al. Angiotensin-(1-7) activates a tyrosine phosphatase and inhibits glucose-induced signalling in proximal tubular cells[J]. Nephrol Dial Transplant, 2009, 24(6): 1766–1773.
[26] Zimpelmann J, Burns K.D. Angiotensin-(1-7) activates growth-stimulatory pathways in human mesangial cells[J]. Am J Physiol Renal Physiol, 2009, 296(2): F337–346.
[27] Al-Maghrebi M, Benter IF, Diz DI. Endogenous angiotensin-(1-7) reduces cardiac ischemia-induced dysfunction in diabetic hypertensive rats[J]. Pharmacol Res, 2009, 59(4): 263-268.
[28] Agrawal A, Dillon S, Denning TL, et al. ERK1?/? mice exhibit Th1 cell polarization and increased susceptibility to experimental autoimmune encephal-omyelitis[J]. J Immunol, 2006, 176(10): 5788-5796.
[29] Nie W, Yan H, Li S, et al. Angiotensin-(1-7) enhances angiotensin II induced phosphorylation of ERK1/2 in mouse bone marrow-derived dendritic cells[J]. Mol Immunol, 2009, 46(3): 355-361.
[30] Liu E, Xu Z, Li J, et al. Enalapril, irbesartan, and angiotensin-(1-7) prevent atrial tachycardia-induced ionic remodeling[J]. Int J Cardiol, 2011, 146(3): 364- 370.
[31] Brundel BJ, van Gelder IC, Henning RH, et al. Gene expression of proteins influencing the calcium homeostasis in patients with persistent and paroxysmal atrial fibrillation[J]. Cardiovasc Res, 1999, 42(2): 443–454.
[32] Grammer JB, Bosch RF, Kühlkamp V, et al. Molecular remodeling of Kv4.3 potassium channels in human atrial fibrillation[J]. J Cardiovasc Electrophysiol, 2000, 11(6): 626–633.
[33] Liu E, Yang S, Xu Z, et al. Angiotensin-(1-7) prevents atrial fibrosis and atrial fibrillation in long-term atrial tachycardia dogs[J]. Regul Pept, 2010, 162(1-3): 73-78.
[34] Dias-Peixoto MF, Santos RA, Gomes ER, et al. Molecular mechanisms involved in the angiotensin-(1-7)/Mas signaling pathway in cardiomyocytes[J]. Hypertension, 2008, 52(3): 542-548.
[35] Gironacci MM, Valera MS, Yujnovsky I, et al. Angiotensin-(1-7) inhibitory mechanism of norepinephrine release in hypertensive rats[J]. Hypertension, 2004, 44(5): 783-787.
[36]钟毅,李家富. ANG(1-7)与高血压保护作用[J].中国心血管病研究,2008, 6 (9): 702-705.
[37] Richard P, Vayre F, Sabouret P, et al. Outcome of traumatic tricuspid insu- fficiency, treated surgically. Apropos of 9 cases[J]. Arch Mal Coeur Vaiss,1997, 90(4): 451-456.
[38] Nelson M, Wells G. A case of traumatic tricuspid valve regurgitation caused by blunt chest trauma[J]. J Am Soc Echocardiogr, 2007, 20(2): 198.e4-5.
[39] Pinheiro SV, Ferreira AJ, Kitten GT, et al. Genetic deletion of the angiotensin- (1-7) receptor Mas leads to glomerular hyperfiltration and microalbuminuria[J]. Kidney Int, 2009, 75 (11) : 1184-1193.
[40] Esteban V, Heringer-Walther S, Sterner-Kock A, et al. Angiotensin-(1-7) and the G protein -coupled receptor MAS are key players in renal inflammation[J]. P LoS One, 2009, 4(4): e5406.
[41] Leal MC, Pinheiro SV, Ferreira AJ, et al. The role of angiotensin-(1-7) receptor Mas in spermatogenesis in mice and rats[J]. J Anat, 2009, 214(5): 736-743.
[42] Kitaoka T, Sharif M, Hanley MR, et al. Expression of the MAS proto-oncogene in the retinal pigment epithelium of the rhesus macaque[J]. Curr Eye Res, 1994, 13(5): 345-351.
[43] Lubel JS, Herath CB, Tchongue J, et al. Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat[J]. Clin Sci (Lond), 2009 , 117(11): 375-386.
[44] Hellner K, Walther T, Schubert M, et al. Angiotensin-(1-7) enhances LTP in the hippocampus through the G-protein-coupled receptor Mas[J]. Mol Cell Neurosci, 2005, 29(3):427-435.
[45] Yoshida M, Naito Y, Urano T, et al. L-158,809 and (D-Ala(7))-angiotensin I/II (1-7) decrease PAI-1 release from human umbilical vein endothelial cells[J]. Thromb Res, 2002, 105(6): 531-536.
[46] Kucharewicz I, Pawlak R, Matys T, et al. Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1-7).Hypertension, 2002, 40(5):774-779.
[2] Mogi M, Iwai M, Horiuchi M. New insights into the regulation of angiotensin receptors[J]. Curr Opin Nephrol Hypertens, 2009, 18: 138-143.
[3]仇燕,朱峰,廖玉华,等.高血压病患者血清抗血管紧张素Ⅱ1型受体自身抗体与心脏重构的相关分析[J].中华心血管病杂志,2007, 35: 1141-1144.
[4]陈秀梅,卢新政,占伊扬,等.血管紧张素Ⅱ2型受体自身抗体与血压水平及肾功能的关系[J].中华高血压杂志,2008, 16: 1071-1075.
[5] Hu L, Zhu DN, Yu Z, et al. Expression of angiotensin II type 1 (AT(1)) receptor in the rostral ventrolateral medulla in rats[J]. J Appl Physiol, 2002, 92: 2153- 2161.
[6] Yayama K, Horii M, Hiyoshi H, et al. Up-regulation of angiotensin II type 2 receptor in rat thoracic aorta by pressure-overload[J]. J Pharmacol Exp Ther, 2004, 308: 736-43.
[7] Allen AM, Zhuo J, Mendelsohn FA. Localization and function of angiotensin AT1 receptors[J]. Am J Hypertens, 2000, 13: 31S-38S.
[8] Reja V, Goodchild AK, Phillips JK, et al. Upregulation of angiotensin AT1 receptor and intracellular kinase gene expression in hypertensive rats[J]. Clin Exp Pharmacol Physiol, 2006, 33: 690–695.
[9] Paxton WG, Runge M, Horaist C, et al. Immunohistochemical localization of rat angiotensinⅡAT1 receptor[J]. Am J Physiol, 1993, 33: F989–F995.
[10] Banday AA, Lokhandwala MF. Loss of biphasic effect on Na/K-ATPase activity by angiotensinⅡinvolves defective angiotensin type 1 receptor-nitric oxide signaling[J]. Hypertension, 2008, 52: 1099-1105.
[11] Hanna IR, Taniyama Y, Szocs K, et al. NADPH oxidase-derived reactiveoxygen species as mediators of angiotensinⅡsignaling[J]. Antioxid Redox Signal, 2002, 4: 899–914.
[12] Gill PS, Wilcox CS. NADPH oxidases in the kidney[J]. Antioxid Redox Signal, 2006, 8: 1597–1607.
[13] Elton TS, Martin MM. Angiotensin II type 1 receptor gene regulation: transcriptional and posttranscriptional mechanisms[J]. Hypertension, 2007, 49 (5): 953-961.
[14] Fu ML, Herlitz H, Wallukat G, et al. Functional autoimmune epitope on alpha 1-adrenergic receptors in patients with malignant hypertension[J]. Lancet, 1994, 344(8938): 1660-1663.
[15] Wallukat G, Homuth V, Fischer T, et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor[J]. J Clin Invest, 1999, 103 (7): 945-952.
[16] Dechend R, Homuth V, Wallukat G, et al. AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor[J]. Circulation, 2000, 101 (20): 2382-2387.
[17] Dechend R, Müller DN, Wallukat G, et al. AT1 receptor agonistic antibodies, hypertension, and preeclampsia[J]. SemSemin Nephrol, 2004, 24(6): 571-579.
[18] Wallukat G, Homuth V, Fischer T, et al. Patients with pre-eclampsia develop agonistic antibodies against the angiotensin AT1R receptor[J]. J Clin Invest, 1999, 103: 945-952.
[19] Sun YX, Zhang HY, Wei YM, et al. The mechanism of signal transduction during vascular smooth muscle cell proliferation induced by autoantibodies against angiotensin AT1 receptor from hypertension[J]. Chin Med J (Engl) , 2008, 121: 43-48.
[20] Yang X, Wang F, Chang H, et al. Autoantibody against AT1 receptor frompreeclamptic patients induces vasoconstriction through angiotensin receptor activation[J]. J Hypertens, 2008, 26: 1629-1635.
[21] LaMarca B, Parrish M, Ray LF, et al. Hypertension in response to auto- antibodies to the angiotensinⅡtype I receptor (AT1-AA) in pregnant rats: role of endothelin-1[J]. Hypertension, 2009, 54: 905-909.
[22] LaMarca B, Wallukat G, Llinas M, et al. Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor alpha in pregnant rats[J]. Hypertension, 2008, 52: 1168-1172.
[23] Parameswaran N, Patial S. Tumor Necrosis Factor-αSignaling in Macrophages [J]. Crit Rev Eukaryot Gene Expr, 2010, 20(2): 87-103.
[24] Clark IA. How TNF was recognized as a key mechanism of disease[J]. Cytokine Growth Factor Rev, 2007, 18(3–4): 335–343.
[25] Kadokami T, McTiernan CF, Kubota T, et al. Sex-related survival differences in murine cardiomyopathy are associated with differences in TNF-receptor expression[J]. J Clin Invest, 2000, 106: 589–597.
[26] Luo D, Luo Y, He Y, et al. Differential functions of tumor necrosis factor receptor 1 and 2 signaling in ischemiamediated arteriogenesis and angiogenesis. Am J Pathol, 2006, 169: 1886–1898.
[27] Kleinbongard P, Schulz R, Heusch G. TNFαin myocardial ischemia/reperfusion, remodeling and heart failure[J]. Heart Fail Rev, 2011, 16(1): 49-69.
[28] Aker S, Belosjorow S, Konietzka I, et al. Serum but not myocardial TNF-a concentration is increased in pacing-induced heart failure in rabbits[J]. Am J Physiol Regul Integr Comp Physiol, 2003, 285: R463–R469.
[29] Marin-Garcia J, Goldenthal MJ, Moe GW. Abnormal cardiac and skeletal muscle mitochond -rial function in pacinginduced cardiac failure[J]. Cardiovasc Res, 2001, 52: 103–110.
[30] Petretta M, Gian L, Condorelli MD, et al. Circulating levels of cytokines and their site of production in patients with mild to severe chronic heart failure[J]. Am Heart J, 2000, 140(6): E28.
[31] Valgimigli M, Ceconi C, Malagutti P, et al. Tumor necrosis factor-a receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction. The cytokine-activation and long-term prognosis in myocardial infarction (C-ALPHA) study[J]. Circulation, 2005, 111: 863–870.
[32] Nikolopoulou A, Tousoulis D, Antoniades C, et al. Common community infecti- ons and the risk for coronary artery disease and acute myocardial infarction: evidence for chronic over-expression of tumor necrosis factor alpha and vascular cells adhesion molecule-1[J]. Int J Cardiol, 2008, 130: 246–250.
[33] Tuomisto K, Jousilahti P, Sundvall J, et al. C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardio- vascular events and total mortality. A population-based, prospective study[J]. Thromb Haemost, 2006, 95: 511–518.
[34] Dinh W, Futh R, Nickl W, et al. Elevated plasma levels of TNF-alpha and interleukin-6 in patients with diastolic dysfunction and glucose metabolism disorders[J]. Cardiovasc Diabetol, 2009, 8:58.
[35] Li JJ, Chen JI. Inflammation may be a bridge connecting hypertension and atheroslerosis[J]. Med Hypotheses, 2005, 64(5): 925-929.
[36] Bautista LE, Vera LM, Arenas IA, et al. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension[J]. J Hum Hypertens, 2005, 19: 149-154.
[37] Kawanabe Y, Nauli SM. Endothelin[J]. Cell Mol Life Sci, 2011, 68(2):195–203.
[38] Price LC, Howard LS. Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy[J]. Am J Cardiovasc Drugs, 2008, 8:171–185.
[39] Shao D, Park JE, Wort SJ.The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension. Pharmacol Res. 2011, [Epub ahead of print].
[40]王平,匡希斌.内皮素-1与原发性高血压[J].心血管病学进展,2007, 28(2):318-320.
[41] Bautista LE, Vera LM, Arenas IA, et al. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension[J]. J Hum Hypertens, 2005, 19(2): 149-154.
[42] Leah S, Jason AP, Mon HS, et al. Endothelin-induced increases in Ca2+ entry mechanisms of vascular contraction are enhanced during high-salt diet[J]. Hypertension, 2003, 41 (part 2): 787-793.
[43] Petnehazy T, Stokes KY, Russell JM, et al. Angiotensin II type-1 receptor antagonism attenuates the inflammatory and thromhogenie responses to hyper- cholesterolemia in venules[J]. Hypertension, 2005, 45(2): 209-215.
[44] Tan M, Lee YJ, Shin SJ, et al. Oxidized low-density lipoprotein stimulates endothlin-1 release and mRNA expression form rat mesangial cells[J]. J Iab Clin Med, 1997, 129: 224-230.
[45] Lüscher TF. Endothelial dysfunction: the role and impact of the renin- angiotensin system[J]. Heart, 2000, 84: i20-i22.
[46]程虹,湛贻璞.内皮素-1与肾素-血管紧张素-醛固酮系统的相互作用[J].肾脏病与透析肾移植杂志,2003, 12(4): 371-374.
[1] Guimar?es S, Pinheiro H. Functional evidence that in the cardiovascular system AT1 angiotensin II receptors are AT1B prejunctionally and AT1A postjunc- tionally[J]. Cardiovasc Res, 2005, 67(2): 208-215.
[2] Saito M, Shinohara Y, Sasaki H, et al. Type 1 angiotensin receptor (AT1-R)- mediated decrease in type 2 angiotensin receptor mRNA level is dependent on Gq and extracellular signal regulated kinase 1//2 in AT1-R-transfected PC12 cells[J]. J Neuroendocrinol, 2008, 20(3): 299-308.
[3] von Bohlen und Halbach O, Albrecht D. The CNS renin-angiotensin system[J]. Cell Tissue Res, 2006, 326(2): 599–616.
[4] Gallinat S, Busche S, Raizada MK, et al.The angiotensin II type 2 receptor: an enigma with multiple variations[J]. Am J Physiol Endocrinol Metab, 2000, 278 (3): E357-E374.
[5] Coffman TM. A genetic approach for studying the physiology of the type 1A (AT1A) angiotensin receptor[J]. Semin Nephrol, 1997, 17(5): 404-411.
[6] Zhou Y, Dirksen WP, Chen Y, et al. A major role for AT1b receptor in mouse mesenteric resistance vessels and its distribution in heart and neuroendocrine tissues[J]. J Mol Cell Cardiol, 2005, 38(4): 693– 696.
[7] Wright JW, Harding JW. Brain angiotensin receptor subtypes AT1, AT2, and AT4 and their functions[J]. Regul Pept, 1995, 59(3): 269-295.
[8] Vanderheyden PM. From angiotensin IV binding site to AT4 receptor[J]. Mol Cell Endocrinol, 2009, 302(2): 159-166.
[9] Paxton WG, Runge M, Horaist C, et al. Immunohistochemical localization of rat angiotensin II AT1 receptor[J]. Am J Physiol, 1993, (6 Pt 2): F989–F995.
[10] Li Z, Iwai M, Wu L, et al. Role of AT2 receptor in the brain in regulation of blood pressure and water intake[J]. Am J Physiol Heart Circ Physiol, 2003,284(1): H116 - H121.
[11] Wright JW, Harding JW. The angiotensin AT4 receptor subtype as a target for the treatment of memory dysfunction associated with Alzheimer's disease[J]. J Renin Angiotensin Aldosterone Syst, 2008, 9(4): 226-237.
[12] Fu ML, Herlitz H, Wallukat G, et al. Functional autoimmune epitope on alpha 1-adrenergic receptors in patients with malignant hypertension[J]. Lancet, 1994, 344(8938): 1660-1663.
[13] Wallukat G, Homuth V, Fischer T, et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor[J]. J Clin Invest, 1999, 103(7): 945-952.
[14] Dechend R, Homuth V, Wallukat G, et al. AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor[J]. Circulation, 2000, 101 (20): 2382-2387.
[15] Dechend R, Müller DN, Wallukat G, et al. AT1 receptor agonistic antibodies, hypertension, and preeclampsia[J]. SemSemin Nephrol, 2004, 24(6): 571-579.
[16] Yang X, Wang F, Chang H, et al. Autoantibody against AT1 receptor from preeclamptic patients induces vasoconstriction through angiotensin receptor activation[J]. J Hypertens, 2008, 26: 1629-1635.
[17] LaMarca B, Parrish M, Ray LF, et al. Hypertension in response to auto- antibodies to the angiotensinⅡtype I receptor (AT1-AA) in pregnant rats: role of endothelin-1[J]. Hypertension, 2009, 54: 905-909.
[18]陈秀梅,卢新政,占伊扬,等.血管紧张素Ⅱ2型受体自身抗体与血压水平及肾功能的关系[J].中华高血压杂志,2008, 16(12): 1071-1075.
[19] Elton TS, Martin MM. Angiotensin II type 1 receptor gene regulation: transcriptional and posttranscriptional mechanisms[J]. Hypertension, 2007, 49 (5): 953-961.
[20] Zhu YC, Zhu YZ, Lu N, et al. Role of angiotensin AT1 and AT2 receptors in cardiac hypertrophy and cardiac remodelling[J]. Clin Exp Pharmacol Physiol, 2003, 30(12): 911-918.
[21] Kim HJ, Ryu JH, Han SW, et al. Combined therapy of cilazapril and losartan has no additive effects in ameliorating adriamycin-induced glomerulopathy[J]. Nephron Physiol, 2004, 97 (4): p58-65.
[22] Reja V, Goodchild AK, Phillips JK, et al. Upregulation of angiotensin AT1 receptor and intracellular kinase gene expression in hypertensive rats[J]. Clin Exp Pharmacol Physiol, 2006, 33(8): 690–695.
[23] Zhou J, Pavel J, Macova M, et al. AT1 receptor blockade regulates the local angiotensin II system in cerebral microvessels from spontaneously hypertensive rats[J]. Stroke, 2006, 37(5): 1271–1276.
[24] Iwai M, Horiuchi M.Devil and angel in the renin–angiotensin system: ACE– angiotensin II–AT1 receptor axis vs. ACE2–angiotensin-(1–7)–Mas receptor axis[J]. Hypertens Res, 2009, 32(7): 533-536.
[25] Kiribayashi K, Masaki T, Naito T, et al. Angiotensin II induces fibronectin expression in human peritoneal mesothelial cells via ERK1/2 and p38 MAPK[J]. Kidney Int, 2005, 67(3): 1126–1135.
[26] Dilauro M, Burns KD. Angiotensin-(1-7) and its effects in the kidney[J]. Scientific World Journal, 2009, 9: 522-535.
[27] Ushio-Fukai M, Alexander RW. Caveolin-dependent angiotensin II type 1 receptor signaling in vascular smooth muscle[J]. Hypertension, 2006, 48(5): 797 -803.
[28] CalòLA, Schiavo S, Davis PA, et al. Angiotensin II signaling via type 2 receptors in a human model of vascular hyporeactivity: implications for hypertension[J]. J Hypertens, 2010, 28(1): 111–118.
[29]首云锋,陈明.血管紧张素受体AT2及AT4研究进展[J].心血管病学进展,2010, 31(1): 58-61.
[30] Chai SY, Fernando R, Peck G, et al. The angiotensin IV/AT4 receptor[J].Cell Mol Life Sci, 2004, 61(21): 2728-2737.
[31] Zorad S, Dou JT, Benicky J, et al. Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARc [J]. Eur J Pharmacol, 2006, 552(1-3): 112–122.
[32] Inaba S, Iwai M, Tomono Y, et al. Exaggeration of focal cerebral ischemia in transgenic mice carrying human Renin and human angiotensinogen genes[J]. Stroke, 2009, 40(2): 597-603.
[33] Horiuchi M, Mogi M, Iwai M. The angiotensin II type 2 receptor in the brain[J]. J Renin Angiotensin Aldosterone Syst, 2010, 11(1): 1-6.
[34] Sakata A, Mogi M, Iwanami J, et al. Sex-different effect of angiotensin II type 2 receptor on ischemic brain injury and cognitive function[J]. Brain Res, 2009, 1300: 14-23.
[35] Wu CK, Tsai CT, Chang YC, et al. Genetic polymorphisms of the angiotensin II type 1 receptor gene and diastolic heart failure[J]. J Hypertens, 2009, 27(3): 502–507.
[36] Wang JL, Xue L, Hao PP,et al. Angiotensin II type 1 receptor gene A1166C polymorphism and essential hypertension in Chinese: a meta-analysis[J]. J Renin Angiotensin Aldosterone Syst, 2010, 11(2): 127-35.
[37] Gao L, Wang WZ, Wang W, et al. Imbalance of angiotensin type 1 receptor and angiotensin II type 2 receptor in the rostral ventrolateral medulla: potential mechanism for sympathetic overactivity in heart failure[J]. Hypertension, 2008, 52(4): 708-714.
[38] Smith GR, Missailidis S. Cancer, inflammation and the AT1 and AT2 receptors [J]. J Inflamm (Lond), 2004, 1(1):3.
[39] De Paepe B, Verstraeten VL, De Potter CR, et al. Growth stimulatory angiotensin II type-1 receptor is upregulated in breast hyperplasia and in situ carcinoma but not in invasive carcinoma[J]. Histochem Cell Biol, 2001, 116(3): 247-254.
[40] Takeda H, Kondo S. Differences between squamous cell carcinoma and keratoa- canthoma in angiotensin type-1 receptor expression[J]. Am J Pathol, 2001, 158 (5): 1633-1637.
[41] Kikkawa F, Mizuno M, Shibata K, et al. Activation of invasiveness of cervical carcinoma cells by angiotensin II[J]. Am J Obstet Gynecol, 2004, 190(5): 1258 -1263.
[42] Suganuma T, Ino K, Shibata K, et al. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination[J]. Clin Cancer Res, 2005, 11(7): 2686-2694.
[43] Fujita M, Hayashi I, Yamashina S, e tal. Angiotensin type 1a receptor signaling- dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth[J]. Carcinogenesis, 2005, 26(2): 271-279.
[44] Faure S, Javellaud J, Achard JM, et al. Vasoconstrictive effect of angiotensin IV in isolated rat basilar artery independent of AT1 and AT2 receptors[J]. J Vasc Res, 2006, 43(1): 19-26.
[45] Lochard N, Thibault G, Silversides DW, et al. Chronic production of angiotensin IV in the brain leads to hypertension that is reversible with an angiotensin II AT1 receptor antagonist[J]. Circ Res, 2004, 94(11): 1451-1457.
[46] Williams PJ, Mistry HD, Innes BA, et al. Expression of AT1R, AT2R and AT4R and their roles in extravillous trophoblast invasion in the human[J]. Placenta, 2010, 31(5): 448-455.
[1] Santos RA, Ferreira AJ,Simoes e AC. Recent advances in the angiotensin converting enzyme 2-angiotensin(1-7)-Mas axis[J]. Exp Physiol, 2008, 93(5): 519–527.
[2] Santos RA, Simoes e Silva AC, Maric C, et al. Angiotensin-(1-7) is an endogenous ligand for the G-protein coupled receptor Mas[J]. Proc Natl Acad Sci U S A, 2003, 100(14): 8258-8263.
[3] Iwai M, Horiuchi M. Devil and angel in the renin–angiotensin system: ACE– angiotensin II–AT1 receptor axis vs. ACE2–angiotensin-(1–7)–Mas receptor axis[J]. Hypertens Res, 2009, 32(7): 533-536.
[4] Xu P, Costa-Goncalves AC, Todiras M, et al. Endothelial Dysfunction and Elevated Blood Pressure in Mas Gene-Deleted Mice[J]. Hypertension, 2008, 51 (2): 574-580.
[5] Towler P, Staker B, Prasad SG, et al. ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis[J]. J Biol Chem, 2004, 279(17): 17996-18007.
[6] Harmer D, Gilbert M, Borman R, et al. Quantitative mRNA expression profiling of ACE2, a novel homologue of angiotensin converting enzyme[J]. FEBS Lett, 2002, 532(1-2): 107-110.
[7] Vickers C, Hales P, Kaushik V, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase[J]. J Biol Chem, 2002, 277(17): 14838-14843.
[8] Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function[J]. Nature, 2002, 417(6891): 822-828.
[9] Santos RA, Brosnihan KB, Jacobsen DW, et al. Production of angiotensin-(1-7) by human vascular endothelium[J]. Hypertension, 1992, 19(2): II56–61.
[10] Joyner J, Neves LA, Granger JP, et al. Temporal-spatial expression of ANG-(1-7) and angiotensin-converting enzyme 2 in the kidney of normal and hypertensive pregnant rats[J]. Am J Physiol Regul Integr Comp Physiol, 2007, 293(1): R169– 177.
[11] Ferrario CM, Martell N, Yunis C, et al. Characterization of angiotensin-(1-7) in the urine of normal and essential hypertensive subjects[J]. Am J Hypertens, 1998, 11(2): 137–146.
[12] Dilauro M, Burns KD. Angiotensin-(1-7) and its effects in the kidney[J]. Scientific World Journal, 2009, 9: 522-535.
[13] Alenina N, Xu P, Rentzsch B, et al. Genetically altered animal models for Mas and angiotensin-(1-7) [J]. Exp Physiol, 2008, 93(5): 528-537.
[14] Burstein ES, Ott TR, Feddock M, et al. Characterization of the Mas-related gene family: structural and functional conservation of human and rhesus MrgX receptors[J]. Br J Pharmacol, 2006, 147(1): 73–82.
[15] Young D, O’Neill K, Jessell T, et al. Characterization of the rat mas oncogene and its high-level expression in the hippocampus and cerebral cortex of rat brain[J]. Proc Natl Acad Sci U S A, 1988, 85(14): 5339–5342.
[16] Alenina N, Baranova T, Smirnow E, et al. Cell type-specific expression of the Mas proto-oncogene in testis[J]. J Histochem Cytochem, 2002; 50(5): 691-696.
[17] Villar AJ, Pedersen RA. Parental imprinting of the Mas protooncogene in mouse[J]. Nature Genet, 1994, 8(4): 373–379.
[18] Metzger R, Bader M, Ludwig T, et al. Expression of the mouse and rat mas proto-oncogene in the brain and peripheral tissues[J]. FEBS Lett, 1995, 357 (1): 27–32.
[19] da Costa Gon?alves AC, Leite R, Fraga-Silva RA, et al. Evidence that the vasodilator angiotensin-(1–7)-Mas axis plays an essential role in erectilefunction[J]. Am J Physiol Heart Circ Physiol, 2007, 293(4): H2588–H2596.
[20] Schluter KD, Wenzel S. Angiotensin II: a hormone involved in and contributing to prohypertrophic cardiac networks and target of anti-hypertrophic cross- talks[J]. Pharmacol Ther, 2008, 119(3): 311–325.
[21] Frank D, Kuhn C, van Eickels M, et al. Calsarcin-1 protects against angiotensin- II induced cardiac hypertrophy[J]. Circulation, 2007, 116(22): 2587–2596.
[22] Gomes ER, Lara AA, Almeida PW, et al. Angiotensin-(1-7) prevents cardio- myocyte pathological remodeling through a nitric oxide/guanosine 3',5'- cyclic monophosphate dependent pathway[J]. Hypertension, 2010, 55(1): 153 -160.
[23] Beals CR, Sheridan CM, Turck CW, et al. Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3[J]. Science, 1997, 275(5308): 1930–1934.
[24] Su Z, Zimpelmann J, Burns KD. Angiotensin-(1-7) inhibits angiotensin II- stimulated phosphorylation of MAP kinases in proximal tubular cells[J]. Kidney Int, 2006, 69 (12): 2212–2218.
[25] Gava E, Samad-Zadeh A, Zimpelmann J, et al. Angiotensin-(1-7) activates a tyrosine phosphatase and inhibits glucose-induced signalling in proximal tubular cells[J]. Nephrol Dial Transplant, 2009, 24(6): 1766–1773.
[26] Zimpelmann J, Burns K.D. Angiotensin-(1-7) activates growth-stimulatory pathways in human mesangial cells[J]. Am J Physiol Renal Physiol, 2009, 296(2): F337–346.
[27] Al-Maghrebi M, Benter IF, Diz DI. Endogenous angiotensin-(1-7) reduces cardiac ischemia-induced dysfunction in diabetic hypertensive rats[J]. Pharmacol Res, 2009, 59(4): 263-268.
[28] Agrawal A, Dillon S, Denning TL, et al. ERK1?/? mice exhibit Th1 cell polarization and increased susceptibility to experimental autoimmune encephal-omyelitis[J]. J Immunol, 2006, 176(10): 5788-5796.
[29] Nie W, Yan H, Li S, et al. Angiotensin-(1-7) enhances angiotensin II induced phosphorylation of ERK1/2 in mouse bone marrow-derived dendritic cells[J]. Mol Immunol, 2009, 46(3): 355-361.
[30] Liu E, Xu Z, Li J, et al. Enalapril, irbesartan, and angiotensin-(1-7) prevent atrial tachycardia-induced ionic remodeling[J]. Int J Cardiol, 2011, 146(3): 364- 370.
[31] Brundel BJ, van Gelder IC, Henning RH, et al. Gene expression of proteins influencing the calcium homeostasis in patients with persistent and paroxysmal atrial fibrillation[J]. Cardiovasc Res, 1999, 42(2): 443–454.
[32] Grammer JB, Bosch RF, Kühlkamp V, et al. Molecular remodeling of Kv4.3 potassium channels in human atrial fibrillation[J]. J Cardiovasc Electrophysiol, 2000, 11(6): 626–633.
[33] Liu E, Yang S, Xu Z, et al. Angiotensin-(1-7) prevents atrial fibrosis and atrial fibrillation in long-term atrial tachycardia dogs[J]. Regul Pept, 2010, 162(1-3): 73-78.
[34] Dias-Peixoto MF, Santos RA, Gomes ER, et al. Molecular mechanisms involved in the angiotensin-(1-7)/Mas signaling pathway in cardiomyocytes[J]. Hypertension, 2008, 52(3): 542-548.
[35] Gironacci MM, Valera MS, Yujnovsky I, et al. Angiotensin-(1-7) inhibitory mechanism of norepinephrine release in hypertensive rats[J]. Hypertension, 2004, 44(5): 783-787.
[36]钟毅,李家富. ANG(1-7)与高血压保护作用[J].中国心血管病研究,2008, 6 (9): 702-705.
[37] Richard P, Vayre F, Sabouret P, et al. Outcome of traumatic tricuspid insu- fficiency, treated surgically. Apropos of 9 cases[J]. Arch Mal Coeur Vaiss,1997, 90(4): 451-456.
[38] Nelson M, Wells G. A case of traumatic tricuspid valve regurgitation caused by blunt chest trauma[J]. J Am Soc Echocardiogr, 2007, 20(2): 198.e4-5.
[39] Pinheiro SV, Ferreira AJ, Kitten GT, et al. Genetic deletion of the angiotensin- (1-7) receptor Mas leads to glomerular hyperfiltration and microalbuminuria[J]. Kidney Int, 2009, 75 (11) : 1184-1193.
[40] Esteban V, Heringer-Walther S, Sterner-Kock A, et al. Angiotensin-(1-7) and the G protein -coupled receptor MAS are key players in renal inflammation[J]. P LoS One, 2009, 4(4): e5406.
[41] Leal MC, Pinheiro SV, Ferreira AJ, et al. The role of angiotensin-(1-7) receptor Mas in spermatogenesis in mice and rats[J]. J Anat, 2009, 214(5): 736-743.
[42] Kitaoka T, Sharif M, Hanley MR, et al. Expression of the MAS proto-oncogene in the retinal pigment epithelium of the rhesus macaque[J]. Curr Eye Res, 1994, 13(5): 345-351.
[43] Lubel JS, Herath CB, Tchongue J, et al. Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat[J]. Clin Sci (Lond), 2009 , 117(11): 375-386.
[44] Hellner K, Walther T, Schubert M, et al. Angiotensin-(1-7) enhances LTP in the hippocampus through the G-protein-coupled receptor Mas[J]. Mol Cell Neurosci, 2005, 29(3):427-435.
[45] Yoshida M, Naito Y, Urano T, et al. L-158,809 and (D-Ala(7))-angiotensin I/II (1-7) decrease PAI-1 release from human umbilical vein endothelial cells[J]. Thromb Res, 2002, 105(6): 531-536.
[46] Kucharewicz I, Pawlak R, Matys T, et al. Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1-7).Hypertension, 2002, 40(5):774-779.